Literature DB >> 15641522

The sad story of Vioxx, and what we should learn from it.

Juhana Karha1, Eric J Topol.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15641522     DOI: 10.3949/ccjm.71.12.933

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


× No keyword cloud information.
  5 in total

1.  A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.

Authors:  Peter G M Mol; Sabine M J M Straus; Sigrid Piening; Jonie T N de Vries; Pieter A de Graeff; Flora M Haaijer-Ruskamp
Journal:  Drug Saf       Date:  2010-06-01       Impact factor: 5.606

2.  [Surgical innovations require testing in controlled clinical studies].

Authors:  D Pieper; E Neugebauer
Journal:  Chirurg       Date:  2016-11       Impact factor: 0.955

3.  Comparative cardiovascular safety of nonsteroidal anti-inflammatory drugs in patients with hypertension: a population-based cohort study.

Authors:  Yaa-Hui Dong; Chia-Hsuin Chang; Li-Chiu Wu; Jing-Shiang Hwang; Sengwee Toh
Journal:  Br J Clin Pharmacol       Date:  2018-03-13       Impact factor: 4.335

4.  Effective use of real-life events as tools for teaching-learning clinical pharmacology in a problem-based learning curriculum.

Authors:  Henry James; Khalid A Al Khaja; Reginald P Sequeira
Journal:  Indian J Pharmacol       Date:  2015 May-Jun       Impact factor: 1.200

5.  Cellular and molecular studies of the effects of a selective COX-2 inhibitor celecoxib in the cardiac cell line H9c2 and their correlation with death mechanisms.

Authors:  K K Sakane; C J Monteiro; W Silva; A R Silva; P M Santos; K F Lima; K C M Moraes
Journal:  Braz J Med Biol Res       Date:  2013-11-29       Impact factor: 2.590

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.